Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma

Hideo Tomihara, Hidetoshi Eguchi, Daisaku Yamada, Kunihito Gotoh, Koichi Kawamoto, Hiroshi Wada, Tadafumi Asaoka, Takehiro Noda, Yutaka Takeda, Masahiro Tanemura, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Preoperative chemoradiotherapy (CRT) is a novel, emerging treatment strategy for pancreatic ductal adenocarcinoma (PDAC), but it remains unclear whether post-surgery adjuvant chemotherapy is feasible following preoperative CRT. This retrospective study evaluates the feasibility of adjuvant therapy after preoperative CRT. Methods: The subjects of this study were 99 consecutive patients who underwent pancreatectomy for PDAC between January, 2007 and February, 2013 in our hospital. Sixty patients received preoperative CRT: as gemcitabine (GEM) and 40 Gy radiation in 28 (G-CRT group), and as GEM, S-1, and 50.4 Gy radiation in 32 (GS-CRT group). We also evaluated 39 patients who underwent surgery alone (SA group). We investigated adjuvant chemotherapy induction and completion rates and the frequency of adverse events rated ≥grade 3, based on Common Terminology Criteria for Adverse Events (version 4.0) in all three groups. Results: In the G-CRT, GS-CRT, and SA groups, the induction rates were 78 % (22/28), 78 % (25/32), and 72 % (28/39), respectively; completion rates were 86 % (19/22), 88 % (22/25), and 82 % (23/28), respectively; and adverse event frequencies were 36 % (8/22), 28 % (7/25), and 43 % (12/28), respectively. No significant difference was found among the three groups. Conclusion: Preoperative CRT was demonstrated to be safe and did not compromise the feasibility of adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)218-226
Number of pages9
JournalSurgery Today
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 1 2017
Externally publishedYes

Fingerprint

Chemoradiotherapy
Adjuvant Chemotherapy
Adenocarcinoma
gemcitabine
Radiation
Pancreatectomy
Terminology
Retrospective Studies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. / Tomihara, Hideo; Eguchi, Hidetoshi; Yamada, Daisaku; Gotoh, Kunihito; Kawamoto, Koichi; Wada, Hiroshi; Asaoka, Tadafumi; Noda, Takehiro; Takeda, Yutaka; Tanemura, Masahiro; Mori, Masaki; Doki, Yuichiro.

In: Surgery Today, Vol. 47, No. 2, 01.02.2017, p. 218-226.

Research output: Contribution to journalArticle

Tomihara, H, Eguchi, H, Yamada, D, Gotoh, K, Kawamoto, K, Wada, H, Asaoka, T, Noda, T, Takeda, Y, Tanemura, M, Mori, M & Doki, Y 2017, 'Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma', Surgery Today, vol. 47, no. 2, pp. 218-226. https://doi.org/10.1007/s00595-016-1405-6
Tomihara, Hideo ; Eguchi, Hidetoshi ; Yamada, Daisaku ; Gotoh, Kunihito ; Kawamoto, Koichi ; Wada, Hiroshi ; Asaoka, Tadafumi ; Noda, Takehiro ; Takeda, Yutaka ; Tanemura, Masahiro ; Mori, Masaki ; Doki, Yuichiro. / Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. In: Surgery Today. 2017 ; Vol. 47, No. 2. pp. 218-226.
@article{48863df5d9084807ade6569115a9f789,
title = "Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma",
abstract = "Purpose: Preoperative chemoradiotherapy (CRT) is a novel, emerging treatment strategy for pancreatic ductal adenocarcinoma (PDAC), but it remains unclear whether post-surgery adjuvant chemotherapy is feasible following preoperative CRT. This retrospective study evaluates the feasibility of adjuvant therapy after preoperative CRT. Methods: The subjects of this study were 99 consecutive patients who underwent pancreatectomy for PDAC between January, 2007 and February, 2013 in our hospital. Sixty patients received preoperative CRT: as gemcitabine (GEM) and 40 Gy radiation in 28 (G-CRT group), and as GEM, S-1, and 50.4 Gy radiation in 32 (GS-CRT group). We also evaluated 39 patients who underwent surgery alone (SA group). We investigated adjuvant chemotherapy induction and completion rates and the frequency of adverse events rated ≥grade 3, based on Common Terminology Criteria for Adverse Events (version 4.0) in all three groups. Results: In the G-CRT, GS-CRT, and SA groups, the induction rates were 78 {\%} (22/28), 78 {\%} (25/32), and 72 {\%} (28/39), respectively; completion rates were 86 {\%} (19/22), 88 {\%} (22/25), and 82 {\%} (23/28), respectively; and adverse event frequencies were 36 {\%} (8/22), 28 {\%} (7/25), and 43 {\%} (12/28), respectively. No significant difference was found among the three groups. Conclusion: Preoperative CRT was demonstrated to be safe and did not compromise the feasibility of adjuvant chemotherapy.",
author = "Hideo Tomihara and Hidetoshi Eguchi and Daisaku Yamada and Kunihito Gotoh and Koichi Kawamoto and Hiroshi Wada and Tadafumi Asaoka and Takehiro Noda and Yutaka Takeda and Masahiro Tanemura and Masaki Mori and Yuichiro Doki",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s00595-016-1405-6",
language = "English",
volume = "47",
pages = "218--226",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma

AU - Tomihara, Hideo

AU - Eguchi, Hidetoshi

AU - Yamada, Daisaku

AU - Gotoh, Kunihito

AU - Kawamoto, Koichi

AU - Wada, Hiroshi

AU - Asaoka, Tadafumi

AU - Noda, Takehiro

AU - Takeda, Yutaka

AU - Tanemura, Masahiro

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: Preoperative chemoradiotherapy (CRT) is a novel, emerging treatment strategy for pancreatic ductal adenocarcinoma (PDAC), but it remains unclear whether post-surgery adjuvant chemotherapy is feasible following preoperative CRT. This retrospective study evaluates the feasibility of adjuvant therapy after preoperative CRT. Methods: The subjects of this study were 99 consecutive patients who underwent pancreatectomy for PDAC between January, 2007 and February, 2013 in our hospital. Sixty patients received preoperative CRT: as gemcitabine (GEM) and 40 Gy radiation in 28 (G-CRT group), and as GEM, S-1, and 50.4 Gy radiation in 32 (GS-CRT group). We also evaluated 39 patients who underwent surgery alone (SA group). We investigated adjuvant chemotherapy induction and completion rates and the frequency of adverse events rated ≥grade 3, based on Common Terminology Criteria for Adverse Events (version 4.0) in all three groups. Results: In the G-CRT, GS-CRT, and SA groups, the induction rates were 78 % (22/28), 78 % (25/32), and 72 % (28/39), respectively; completion rates were 86 % (19/22), 88 % (22/25), and 82 % (23/28), respectively; and adverse event frequencies were 36 % (8/22), 28 % (7/25), and 43 % (12/28), respectively. No significant difference was found among the three groups. Conclusion: Preoperative CRT was demonstrated to be safe and did not compromise the feasibility of adjuvant chemotherapy.

AB - Purpose: Preoperative chemoradiotherapy (CRT) is a novel, emerging treatment strategy for pancreatic ductal adenocarcinoma (PDAC), but it remains unclear whether post-surgery adjuvant chemotherapy is feasible following preoperative CRT. This retrospective study evaluates the feasibility of adjuvant therapy after preoperative CRT. Methods: The subjects of this study were 99 consecutive patients who underwent pancreatectomy for PDAC between January, 2007 and February, 2013 in our hospital. Sixty patients received preoperative CRT: as gemcitabine (GEM) and 40 Gy radiation in 28 (G-CRT group), and as GEM, S-1, and 50.4 Gy radiation in 32 (GS-CRT group). We also evaluated 39 patients who underwent surgery alone (SA group). We investigated adjuvant chemotherapy induction and completion rates and the frequency of adverse events rated ≥grade 3, based on Common Terminology Criteria for Adverse Events (version 4.0) in all three groups. Results: In the G-CRT, GS-CRT, and SA groups, the induction rates were 78 % (22/28), 78 % (25/32), and 72 % (28/39), respectively; completion rates were 86 % (19/22), 88 % (22/25), and 82 % (23/28), respectively; and adverse event frequencies were 36 % (8/22), 28 % (7/25), and 43 % (12/28), respectively. No significant difference was found among the three groups. Conclusion: Preoperative CRT was demonstrated to be safe and did not compromise the feasibility of adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84984852027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984852027&partnerID=8YFLogxK

U2 - 10.1007/s00595-016-1405-6

DO - 10.1007/s00595-016-1405-6

M3 - Article

VL - 47

SP - 218

EP - 226

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 2

ER -